A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia

Simple item page
dc.contributor.authorEmsley R.
dc.contributor.authorTurner H.J.
dc.contributor.authorSchronen J.
dc.contributor.authorBotha K.
dc.contributor.authorSmit R.
dc.contributor.authorOosthuizen P.P.
dc.date.accessioned2011-05-15T16:01:56Z
dc.date.available2011-05-15T16:01:56Z
dc.date.issued2004
dc.description.abstractBackground: While the atypical antipsychotics should ultimately reduce the prevalence of tardive dyskinesia, it is likely to remain a significant clinical problem for a long time to come. No strategy has clearly emerged as the treatment of choice for tardive dyskinesia. Atypical antipsychotics have reduced propensities for producing acute extrapyramidal symptoms (EPS) and possibly tardive dyskinesia and may be effective in treating patients with established tardive dyskinesia. Method: This 12-month, randomized, investigator-blinded study compared the efficacy of quetiapine (N = 22) and haloperidol (N = 23) in treating patients with DSM-IV schizophrenia or schizoaffective disorder and established tardive dyskinesia. Dyskinesia was assessed using the Extrapyramidal Symptom Rating Scale (ESRS) dyskinesia subscale scores and the Clinical Global Impression (CGI) dyskinesia scores. Other EPS, weight, serum prolactin level, and glycosylated hemoglobin level were also assessed. Subjects were enrolled in the study between April 2000 and March 2002. Results: Mean endpoint doses were 400 mg/day of quetiapine and 8.5 mg/day of haloperidol. Compared with the haloperidol group, the quetiapine group showed significantly greater improvements in ESRS dyskinesia (6 and 9 months [p ≤ .01]) and CGI dyskinesia (from 6 months onward [p < .05] and with repeated-measures analysis [p = .002]). Response rate (≥ 50% symptom reduction) was greater with quetiapine than haloperidol (64% [9/14] and 37% [6/16] at 6 months; 55% [6/11] and 28% [4/14] at 12 months). Other EPS decreased significantly with quetiapine at 3 (p = .01), 6 (p = .01), and 9 (p = .002) months. Serum prolactin levels decreased with quetiapine but increased with haloperidol, differing significantly between the groups at endpoint (p = .005). No significant changes in weight or glucose metabolism were recorded in either group. Conclusion: Quetiapine effectively reduces the severity of tardive dyskinesia and is well tolerated in patients with established tardive dyskinesia. © Copyright 2004 Physicians Postgraduate Press, Inc.
dc.description.versionArticle
dc.identifier.citationJournal of Clinical Psychiatry
dc.identifier.citation65
dc.identifier.citation5
dc.identifier.issn1606689
dc.identifier.other10.4088/JCP.v65n0516
dc.identifier.urihttp://hdl.handle.net/10019.1/12229
dc.subjectdibenzothiazepine derivative
dc.subjecthaloperidol
dc.subjectneuroleptic agent
dc.subjectquetiapine
dc.subjectadult
dc.subjectarticle
dc.subjectclinical trial
dc.subjectcomparative study
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdrug administration
dc.subjectdyskinesia
dc.subjectfemale
dc.subjecthospitalization
dc.subjecthuman
dc.subjectmale
dc.subjectmiddle aged
dc.subjectpsychological aspect
dc.subjectpsychology
dc.subjectpsychosis
dc.subjectrandomized controlled trial
dc.subjectschizophrenia
dc.subjectsingle blind procedure
dc.subjecttreatment outcome
dc.subjectAdult
dc.subjectAntipsychotic Agents
dc.subjectDibenzothiazepines
dc.subjectDrug Administration Schedule
dc.subjectDyskinesia, Drug-Induced
dc.subjectFemale
dc.subjectHaloperidol
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPsychotic Disorders
dc.subjectSchizophrenia
dc.subjectSchizophrenic Psychology
dc.subjectSeverity of Illness Index
dc.subjectSingle-Blind Method
dc.subjectTreatment Outcome
dc.titleA single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications